Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.
Nearly one-third of the cohort — which included patients with multiple tumor types — responded to therapy. Those with non-small cell lung cancer and pancreatic cancer derived the most benefit.
“We hoped and expected that zenocutuzumab would be effective in patients with NRG1-positive cancers; however, it was nonetheless very exciting to see these results,” Alison M. Schram, MD, gynecologic medical oncologist and